2 days Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates Zacks
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of 34.88% and 5.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
X